An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options to purchase 1,800 shares of the company’s common stock and restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. The stock options have an exercise price of $31.37 per share, a ten-year term, and vest over four years. The RSUs also vest over four years, with 25 percent vesting after 12 months of continuous service and the balance vesting in successive installments. These grants were made as a material inducement to the employees’ acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
None.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on December 13, 2023, the company granted (i) non-statutory stock options to purchase 1,800 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.
The stock options have an exercise price of $31.37 per share, equal to the closing price of Schrödinger’s common stock on December 13, 2023. The stock options have a ten-year term and vest over four years, with 25 percent of the shares underlying the option vesting when the employee completes 12 months of continuous service measured from the employment start date and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon the employee’s completion of each additional month of service over the 36-month period following the first anniversary of the employment start date.
The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee’s completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date.
The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company’s 2021 Inducement Equity Incentive Plan.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The computational platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.
Founded in 1990, Schrödinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.
Schrödinger, Inc. (Nasdaq: SDGR) reported granting non-statutory stock options and restricted stock units (RSUs) to three newly hired employees.
How many shares were included in the stock options and RSUs grants?
The company granted non-statutory stock options to purchase 1,800 shares of the company’s common stock and RSUs with respect to 2,250 shares of the company’s common stock to three newly hired employees.
What is the exercise price of the stock options?
The stock options have an exercise price of $31.37 per share.
How long is the term for the stock options?
The stock options have a ten-year term.
How do the stock options and RSUs vest?
The stock options and RSUs both vest over four years, with 25 percent vesting after 12 months of continuous service and the balance vesting in successive installments.
What is the purpose of these grants?
The grants were made as a material inducement to the employees’ acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).